Psoriatic arthritis: Epidemiology, diagnosis, and treatment

Table 3 Summary of current biologic therapies for the treatment of psoriasis and psoriatic arthritis[63-65]

Drug	Treatment
Anti-TNF
Adalimumab	PsA: 40 mg sc every other week. Psoriasis: 80 mg sc at week 0, 40 mg sc every other week thereafter
Etanercept	PsA: 25 mg sc twice per week. Psoriasis: 50 mg sc twice weekly for 3 mo, 50 mg/wk thereafter
Golimumab	PsA: 50 mg sc every month
Infliximab	PsA and psoriasis: 5 mg/kg at week 0, 2, and 6, every 8 wk thereafter
Anti-IL-17
Brodalumab	In clinical trials
Ixekizumab	In clinical trials
Secukinumab	In clinical trials
Anti-IL-12/IL-23
Briakinumab	In clinical trials
Ustekinumab	Psoriasis: 45 mg (weight < 100 kg) or 90 mg (weight > 100 kg) sc at wk 0 and 4, followed by 45 mg or 90 mg every 12 wk
Anti-T cell activation
Alefacept	Psoriasis: 15 mg IM weekly for 12 wk

PsA: Psoriatic arthritis; SC: Subcutaneous injection; IM: Intramuscular injection; TNF: Tumor necrosis factor; IL: Interleukin.